Daniel R Van Langenberg

List of Publications by Citations

60 papers	1,262 citations	20 h-index	34 g-index
71 ext. papers	1,512 ext. citations	3.4 avg, IF	4.62 L-index

#	Paper	IF	Citations
60	Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 1037-1053	6.1	165
59	Systematic review: fatigue in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 131-43	6.1	132
58	Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome. *Journal of Human Nutrition and Dietetics*, **2014**, 27 Suppl 2, 263-75	3.1	78
57	A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. *Journal of Crohnss and Colitis*, **2012**, 6, 302-10	1.5	78
56	Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2013**, 19, 2906-18	4.5	59
55	Functional gastrointestinal disorders in inflammatory bowel disease: impact on quality of life and psychological status. *Journal of Gastroenterology and Hepatology (Australia)*, **2011**, 26, 916-23	4	58
54	Factors associated with physical and cognitive fatigue in patients with Crohnꞌs disease: a cross-sectional and longitudinal study. *Inflammatory Bowel Diseases*, **2014**, 20, 115-25	4.5	49
53	Un-promoted issues in inflammatory bowel disease: opportunities to optimize care. *Internal Medicine Journal*, **2010**, 40, 173-82	1.6	41
52	Objectively measured muscle fatigue in Crohnꞌs disease: correlation with self-reported fatigue and associated factors for clinical application. *Journal of Crohnss and Colitis*, **2014**, 8, 137-46	1.5	39
51	Delving into disability in Crohnꞌs disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohnꞌs disease. *Journal of Crohnss and Colitis*, **2014**, 8, 626-34	1.5	39
50	Chronic pain in inflammatory bowel disease: characteristics and associations of a hospital-based cohort. *Inflammatory Bowel Diseases*, **2013**, 19, 1210-7	4.5	38
49	Sleep and physical activity measured by accelerometry in Crohnꞌs disease. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 991-1004	6.1	37
48	Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?. *World Journal of Gastroenterology*, **2017**, 23, 6385-6402	5.6	31
47	The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: a single metropolitan Australian center experience. *Journal of Crohnss and Colitis*, **2010**, 4, 413-21	1.5	30
46	Intra-patient variability in adalimumab drug levels within and between cycles in Crohnꞌs disease. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 1135-1145	6.1	29
45	Adverse clinical phenotype in inflammatory bowel disease: a cross sectional study identifying factors potentially amenable to change. *Journal of Gastroenterology and Hepatology (Australia)*, **2010**, 25, 1250-8	4	28
44	Cognitive impairment in Crohnꞌs disease is associated with systemic inflammation, symptom burden and sleep disturbance. *United European Gastroenterology Journal*, **2017**, 5, 579-587	5.3	27

43	Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis. *Inflammatory Bowel Diseases*, **2016**, 22, 2966-2976	4.5	27
42	Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. *Journal of Crohns and Colitis*, **2018**, 12, 289-297	1.5	24
41	Predicting response after infliximab salvage in acute severe ulcerative colitis. *Journal of Gastroenterology and Hepatology (Australia)*, **2018**, 33, 1347-1352	4	24
40	Assessing patient satisfaction in inflammatory bowel disease using the QUOTE-IBD survey: a small step for clinicians, a potentially large step for improving quality of care. *Journal of Crohns and Colitis*, **2013**, 7, e367-74	1.5	20
39	Cytomegalovirus disease, haemophagocytic syndrome, immunosuppression in patients with IBD: a cocktail best avoided, not stirred! *Journal of Crohns and Colitis*, **2011**, 5, 469-72	1.5	18
38	Inflammatory bowel disease serology in Asia and the West. *World Journal of Gastroenterology*, **2013**, 19, 6207-13	5.6	16
37	Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease. *Digestive and Liver Disease*, **2018**, 50, 682-688	3.3	15
36	Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease. *Journal of Crohns and Colitis*, **2018**, 12, 280-288	1.5	15
35	A dedicated inflammatory bowel disease service quantitatively and qualitatively improves outcomes in less than 18 months: a prospective cohort study in a large metropolitan centre. *Frontline Gastroenterology*, **2012**, 3, 137-142	2.6	14
34	Satisfaction with patient-doctor relationships in inflammatory bowel diseases: examining patient-initiated change of specialist. *World Journal of Gastroenterology*, **2012**, 18, 2212-8	5.6	11
33	Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2019**, 25, 1462-1473	4.5	10
32	Poor predictive value of breath hydrogen response for probiotic effects in IBS. *Journal of Gastroenterology and Hepatology (Australia)*, **2015**, 30, 1731-9	4	9
31	Inflammatory Bowel Disease Clinical. *Journal of Gastroenterology and Hepatology (Australia)*, **2017**, 32, 121-154	4	8
30	Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis. *Journal of Gastroenterology and Hepatology (Australia)*, **2018**, 33, 226-231	4	7
29	Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. *Internal Medicine Journal*, **2019**, 49, 94-100	1.6	7
28	The potential value of faecal lactoferrin as a screening test in hospitalized patients with diarrhoea. *Internal Medicine Journal*, **2010**, 40, 819-27	1.6	7
27	Changing face of care for patients with moderate to severe inflammatory bowel disease: the role of specialist nurses in the governance of anti-TNF prescribing. *Internal Medicine Journal*, **2015**, 45, 1161-6	1.6	6
26	Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 1174-1184	6.1	6

25	Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease. *Digestive Diseases and Sciences*, **2019**, 64, 1622-1631	4	6
24	Potentially avoidable surgery in inflammatory bowel disease: what proportion of patients come to resection without optimal preoperative therapy? A guidelines-based audit. *Internal Medicine Journal*, **2012**, 42, e84-8	1.6	5
23	Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy. *Intestinal Research*, **2021**,	4.1	5
22	Characterization of ulcerative colitis-associated constipation syndrome (proximal constipation). *JGH Open*, **2018**, 2, 217-222	1.8	5
21	A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab early colectomy. *Therapeutic Advances in Chronic Disease*, **2019**, 10, 2040622319825595	4.9	4
20	A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 1342-1352	6.1	4
19	Inflammatory Bowel Disease, Clinical. *Journal of Gastroenterology and Hepatology (Australia)*, **2009**, 24, A311-A321	4	4
18	Gastrointestinal: acute haemorrhage from a Dieulafoy lesion within a gastric diverticulum managed endoscopically. *Journal of Gastroenterology and Hepatology (Australia)*, **2009**, 24, 1891	4	4
17	Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn's Disease. *Journal of Crohns and Colitis*, **2021**, 15, 583-593	1.5	4
16	The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era. *Inflammatory Bowel Diseases*, **2020**, 26, 369-379	4.5	2
15	The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease. *Intestinal Research*, **2021**, 19, 158-170	4.1	2
14	Inflammatory Bowel Disease Helpline Reduces Subsequent Inpatient Admission Rates. *Journal of Crohns and Colitis*, **2020**, 14, 281	1.5	2
13	Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 561-562	6.1	1
12	Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 564-565	6.1	1
11	Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease. *Research in Social and Administrative Pharmacy*, **2021**, 17, 1420-1425	2.9	1
10	Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it!. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 1028-1029	6.1	1
9	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Optimising Therapeutic Effectiveness of Biologics **2019**, 243-255		0
8	Medical Management of Infliximab Failure in Acute Severe Ulcerative Colitis. *Journal of Crohns and Colitis*, **2020**, 14, 1029	1.5	0

List of Publications

7	Aminosalicylate withdrawal following escalation to immunomodulators or biologics in ulcerative colitis: cost saving, convenient and does not compromise efficacy. *GastroHep*, **2020**, 2, 57-63	1	0
6	Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's disease.. *Therapeutic Advances in Gastroenterology*, **2022**, 15, 17562848211070940	4.7	0
5	Inflammatory bowel disease and superior mesenteric artery thromboembolism. *Intestinal Research*, **2020**, 18, 130-133	4.1	0
4	Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an Australian experience - effective, safe, yet room for improvement. *Internal Medicine Journal*, **2021**, 51, 106-110	1.6	0
3	Are all symptoms in patients in IBD due to occult inflammation?. *American Journal of Gastroenterology*, **2010**, 105, 2703; author reply 2703-4	0.7	
2	New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD. *Journal of Gastroenterology and Hepatology (Australia)*, **2016**, 31 Suppl 1, 10-1	4	
1	Letter: rationalising aminosalicylates in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 1619-1620	6.1	